OPEN END TURBO LONG - GENMAB | Delayed Börse Stuttgart 09:58:56 2024-07-11 am EDT | ||
| 3.39 EUR | +16.49% |
|
| Current month | +5.05% | ||
| 1 month | -43.16% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 3.39 | +16.49% |
| 24-07-10 | 2.91 | -1.69% |
| 24-07-09 | 2.96 | +6.47% |
| 24-07-08 | 2.78 | -1.07% |
| 24-07-05 | 2.81 | +8.91% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 09:58 am EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | Morgan Stanley |
| WKN | ME8RV8 |
| ISIN | DE000ME8RV81 |
| Date issued | 2024-02-14 |
| Strike | 1,552 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.71 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.7 € |
|---|---|
| Lowest since issue | 2.12 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,765
DKK
Average target price
2,446
DKK
Spread / Average Target
+38.60%
- Stock Market
- Certificates
- Certificat
